Free GLP-1 tool · No sign-up

How much weight can I lose on Mounjaro, Wegovy or Ozempic?

For people already prescribed GLP-1 medication. Weight Easy does not prescribe, sell or arrange medication. Your prescriber makes treatment and dose decisions.

By the Weight Easy Editorial Team ·

Quick answer: In the main trials, people lost an average of 15% to 21% of their body weight on tirzepatide (Mounjaro, Zepbound) over 72 weeks and about 15% on semaglutide 2.4 mg (Wegovy) over 68 weeks. People with type 2 diabetes lost less, about 9% to 15%. Enter your details to get your week-by-week projection in the free Weight Easy app.

Type 2 diabetes?
Units

The dose your prescriber plans to keep you on, and the trial it comes from.

kg
kg

Fill in the form to see your result

Still needed: your medication, whether you have type 2 diabetes, your planned maintenance dose, your starting weight.

Works with: Mounjaro, Zepbound, Ozempic, Wegovy, Wegovy pill, Rybelsus, Ozempic tablets, Saxenda, Victoza, Trulicity, Bydureon BCise, Byetta, Foundayo, Yurpeak, Obeda, Noveltreat, Semaglyn, Sematrinity, GLIPIQ, compounded semaglutide, compounded tirzepatide.

Free to download

See if you're on track, week by week

Log your weight in Weight Easy and see your own trend over weeks, not days. When progress slows, ask Weight Easy's AI coach what to change, from protein to questions worth asking your doctor.

  • Weight and waist trends over weeks
  • Weekly check-ins that ignore daily noise
  • Protein and muscle tips from a dietitian-built plan
  • Ask Weight Easy's AI coach about a plateau any time

Free to download. Subscription for full features, with a 7-day free trial on the yearly plan. For people already prescribed GLP-1 medicine. Weight Easy does not prescribe, sell or arrange medicine. Follow the treatment instructions from your prescribing clinician.

Read the complete guide

The calculator stays free on this page. Its longer explanatory article, medicine-specific FAQ and cited sources live in the Weight Easy blog, alongside the other health and tracking guides.

Read the guide and FAQ →

Related guides

Sources and limits

  • STEP 1, Wilding et al., NEJM 2021; STEP 2, Davies et al., Lancet 2021; STEP UP, Lancet Diabetes Endocrinol 2025.
  • SURMOUNT-1, Jastreboff et al., NEJM 2022; SURMOUNT-2, Garvey et al., Lancet 2023; SURMOUNT-5, NEJM 2025.

This tool is for education. It does not diagnose, prescribe or change a dose. Always follow your prescriber and the leaflet that came with your medication.